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Introduction
The p53 transcription factor is activated by inappropriate cell 
growth stimulation or by certain types of DNA damage and reg-
ulates the expression of other genes involved in cell growth 
  arrest, DNA repair, and apoptosis (Vousden, 2000). These vari-
ous p53-mediated effects suppress tumorigenesis, and mutation 
of the p53 gene or of the p53 signaling pathway is commonly 
found in most human cancers (Soussi and Beroud, 2001). 
  Although the ability of p53 to regulate cell growth after expo-
sure to stress has been well established, the role of p53 in regu-
lating normal (nondamaged) cell growth and in tissue homeostasis 
is uncertain. Mice deleted for p53 will form tumors with 100% 
penetrance yet undergo normal development (Donehower et al., 
1992), albeit with a reduction from the expected numbers of 
  female births and a small percentage of embryos presenting at 
C.J. Lengner and H.A. Steinman contributed equally to this work.
Correspondence to Stephen N. Jones: stephen.jones@umassmed.edu
C.J. Lengner’s present address is Whitehead Institute for Biomedical Research, 
Cambridge, MA 02142.
J. Gagnon’s present address is Department of Molecular Biology, Cell Biology, 
and Biochemistry, Brown University, Providence, RI 02912.
Abbreviations used in this paper: E, embryonic day; GAPDH, glyseraldehyde-3-
phosphate dehydrogenase; micro-CT, microcomputed tomography.
C.J. Lengner and H.A. Steinman contributed equally to this work.
Correspondence to Stephen N. Jones: stephen.jones@umassmed.edu
C.J. Lengner’s present address is Whitehead Institute for Biomedical Research, 
Cambridge, MA 02142.
J. Gagnon’s present address is Department of Molecular Biology, Cell Biology, 
and Biochemistry, Brown University, Providence, RI 02912.
Abbreviations used in this paper: E, embryonic day; GAPDH, glyseraldehyde-3-
phosphate dehydrogenase; micro-CT, microcomputed tomography.
midgestation with exencephaly (Armstrong et al., 1995; Sah 
et al., 1995). In addition, transgenic mice bearing a reporter gene 
under transcriptional control of a p53 response element reveal 
little or no postnatal p53 activity in the absence of DNA damage 
(Gottlieb et al., 1997). These fi  ndings suggest that p53 is impor-
tant in suppressing tumorigenesis but is largely dispensable for 
normal cell growth, cell differentiation, and development.
In contrast, a recently generated mouse model bearing a 
mutated p53 allele (m allele) that increased p53 activity in vitro 
displayed early aging-like phenotypes, including reduced mass 
of various internal organs, thinning of the dermis, hair loss, and 
osteoporosis (Tyner et al., 2002). Interestingly, the p53 m/+ 
mice also had reduced incidence of cancer relative to p53 het-
erozygous (−/+) mice, suggesting that the mutant allele in-
creased p53 activity encoded by the wild-type p53 gene in the 
m/+ mice. Although this increase in basal levels of p53 activity 
offered further protection from neoplasia, the authors hypothe-
sized that the slight increase in p53 activity also reduced stem 
cell proliferation in affected tissues leading to reduced tissue 
cellularity. These results suggest that negative regulation of 
p53-induced apoptosis or inhibition of cell growth might be 
  important to maintain proper tissue homeostasis in adult mice.
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M
dm2 is required to negatively regulate p53 
  activity at the peri-implantation stage of early 
mouse development. However, the absolute 
  requirement for Mdm2 throughout embryogenesis and 
in organogenesis is unknown. To explore Mdm2–p53 
signaling in osteogenesis, Mdm2-conditional mice were 
bred with Col3.6-Cre–transgenic mice that express Cre 
recombinase in osteoblast lineage cells. Mdm2-conditional 
Col3.6-Cre mice die at birth and display multiple skeletal 
defects. Osteoblast progenitor cells deleted for Mdm2 
have elevated p53 activity, reduced proliferation, reduced 
levels of the master osteoblast transcriptional regulator 
Runx2, and reduced differentiation. In contrast, p53-null 
osteoprogenitor cells have increased proliferation, in-
creased expression of Runx2, increased osteoblast matu-
ration, and increased tumorigenic potential, as mice 
speciﬁ  cally deleted for p53 in osteoblasts   develop osteo-
sarcomas. These results demonstrate that p53 plays a 
critical role in bone organogenesis and homeostasis 
by negatively regulating bone development and growth 
and by suppressing bone neoplasia and that Mdm2-
  mediated inhibition of p53 function is a prerequisite for 
Runx2   activation, osteoblast differentiation, and proper 
skeletal formation.JCB • VOLUME 172 • NUMBER 6 • 2006  910
Mdm2 is a key negative regulator of p53 activity in the 
cell. Mdm2 complexes with p53 and negatively regulates p53-
induced transcription of target genes, including the Mdm2 gene 
(for review see Iwakuma and Lozano, 2003). During times of 
cellular insult, p53 activates Mdm2 gene expression by binding 
to a p53 response element within the fi  rst intron of the Mdm2 
gene (Juven et al., 1993). Induction of Mdm2 protein levels 
leads to an increase in Mdm2–p53 complex formation that in-
terferes with the ability of p53 to transactivate Mdm2. Thus, 
Mdm2 expression is autoregulated because of the ability of 
Mdm2 to negatively regulate p53 (Wu et al., 1993). Mdm2 has 
been shown to interfere with the ability of p53 to transactivate 
target genes by binding and stearically hindering the NH2-
  terminal activation domain of the p53 protein (Momand et al., 
1992; Chen et al., 1995) or by altering p53 protein modifi  ca-
tions that regulate p53 transcriptional activation (Xirodimas 
et al., 2004). In addition, Mdm2 can function as an E3 ligase to 
  coordinate the ubiquitination of p53 (Honda et al., 1997) and 
can induce the degradation of p53 by the 26S proteasome (Haupt 
et al., 1997; Kubbutat et al., 1997; Li et al., 2003). Mdm2 can 
also assist in shuttling p53 from the nucleus into the cytoplasm 
(  Freedman and Levine, 1998; Geyer et al., 2000). The impor-
tance of Mdm2 in negatively regulating p53 activity is perhaps 
best illustrated by the fi  nding that the early (embryonic day [E] 
4–5) lethal phenotype of Mdm2-null mice can be fully rescued 
by the concomitant deletion of p53 (Jones et al., 1995; Montes 
de Oca Luna et al., 1995).
Although the requirement for Mdm2-mediated inhibi-
tion of p53 activity during early development has been well 
established, the role of Mdm2 in regulating p53 functions in 
later stages of embryogenesis or in adult tissues is unclear. 
However, several lines of evidence suggest that Mdm2 does 
function to regulate p53 activity in postnatal tissue. EuMyc 
transgenic mice display a delayed onset of B cell lymphoma 
when haploinsuffi  cient for Mdm2, suggesting that a reduction 
in Mdm2-mediated suppression of p53 can reduce tumorigen-
esis (Alt et al., 2003). In addition, mice bearing a hypomorphic 
allele of Mdm2 that have  30% of the normal endogenous 
levels of Mdm2 are smaller in size, have reduced numbers of 
hematopoietic cells, and display excess apoptosis in the lym-
phoid compartment (Mendrysa et al., 2003). Crossing the 
Mdm2 hypomorphic allele onto a p53-defi  cient background 
reversed the various phenotypes observed in these mice, dem-
onstrating that the phenotypic effects caused by Mdm2 reduc-
tion in this model were induced by p53. These data suggest 
that Mdm2 is capable of negatively regulating p53 activity in 
hematopoietic tissues.
To determine the absolute requirement for Mdm2 during 
development and in adult tissues, we have recently used Cre-
loxP technology to generate Mdm2-conditional mice. Gene tar-
geting experiments in embryonic stem cells fl  anked the last two 
exons of the Mdm2 gene encoding the zinc RING (really inter-
esting new gene) fi  nger domains and polyadenylation signals 
with loxP sites. Cre-mediated recombination of the loxP sites in 
the conditional allele destabilizes Mdm2 transcripts and results 
in loss of Mdm2 message. (Steinman and Jones, 2002). Because 
studies of p53 mutant mice suggest that excess p53 activity 
might have a deleterious effect on normal bone   homeostasis, we 
sought to determine whether Mdm2 regulates p53 activity dur-
ing   osteogenesis. To this end, Mdm2- or p53-conditional mice 
were bred with transgenic mice in which the Cre-  recombinase 
gene has been placed under transcriptional control of a 3.6-kb 
fragment of the Coll1a1 promoter. These Col3.6-Cre– transgenic 
mice have been previously reported to express Cre in cells of 
the osteoblast lineage (Liu et al., 2004). Mdm2-conditional 
mice bearing the Col3.6 transgene have multiple skeletal de-
fects, including fused or otherwise altered lumbar vertebrae, re-
duced mineralized bone, and reduced bone length. Osteoblasts 
deleted for Mdm2 do not undergo apoptosis but do have ele-
vated p53 activity, increased transactivation of p53   target genes, 
reduced cell proliferation, and reduced   levels of the osteoblast 
transcriptional regulator Runx2, which is essential for osteo-
blast differentiation (Banerjee et al., 1997; Ducy et al., 1997; 
Komori et al., 1997). In contrast, osteoblasts deleted for p53 
display elevated Runx2 levels, enhanced cell proliferation, and 
Figure 1.  Expression of Cre recombinase in Col3.6-Cre–transgenic mice. 
(A) PCR performed using Cre primers on reverse-transcribed RNA isolated 
from adult Col3.6-Cre–transgenic mice. Primers to GAPDH were used as a 
positive control in the RT-PCR, whereas non–reverse-transcribed (No RT) rib 
bone RNA, liver RNA, and water (H20) were used as negative controls for 
the PCR. Cre expression is readily detected in the rib and femur of these 
mice. (B) Whole-mount staining of lacZ expression in Col3.6-Cre–transgenic 
R26R embryos at E10, -12.5, and -15.5 during development. Expression of 
the Cre recombinase as detected by β-galactosidase activity is detected in 
surface ectoderm and in the caudal portion of the embryo at E10, with the 
highest levels found in the tail bud (arrow). Between E12.5 and -15.5, the 
Col3.6-Cre transgene undergoes robust activation with the formation of con-
nective tissue. (C) Staining for β-galactosidase activity in sagital sections of 
R26R/Col3.6-Cre embryos indicates that Cre-mediated excision occurs in 
both the skin and developing skeletal elements at E12.5–14.5.MDM2–P53 REGULATION OF OSTEOGENESIS • LENGNER ET AL. 911
increased maturation and mineralization. Furthermore, mice 
specifi  cally deleted for p53 in osteoblast progenitor cells de-
velop osteosarcomas. These results demonstrate that p53 is an 
important negative regulator of osteogenesis and that Mdm2-
mediated inhibition of p53 function is a critical requirement 
for Runx2 activation and proper osteoblast differentiation and 
 skeletal  formation.
Results
Expression of Cre recombinase 
in Col3.6-Cre–transgenic mice
To understand the contribution of Mdm2 and p53 signaling to 
bone development, we used Mdm2-conditional mice bearing 
Mdm2 genes (Mdm2
sjcnd1) with loxP recombination sites fl  ank-
ing exons 11 and 12 (Steinman and Jones, 2002). Deletion of 
these exons will result in loss of Mdm2 in cells expressing the 
P1 bacteriophage Cre-recombinase transgene under transcrip-
tional control of a rat 3.6-kb type I collagen promoter fragment 
(Liu et al., 2004). This transgene has been reported to induce 
Cre-mediated gene excision in postnatal calvarial bone and long 
bone osteoblasts, as well as in skin and tendons. We initially 
verifi  ed the expression of Cre in skeletal elements of adult mice. 
RT-PCR reactions using RNA isolated from the rib and femur of 
adult Col3.6-Cre mice demonstrated Cre expression in these tis-
sues, whereas Cre transcripts were not detected in other tested 
organs (Fig. 1 A). To identify regions in Col3.6-Cre developing 
embryos that express Cre and induce Cre-mediated excision, 
we mated the Col3.6-Cre–transgenic mice to ROSA26 (R26R) 
reporter mice that express β-galactosidase upon Cre-  induced 
deletion of a fl  oxed cassette that inhibits the reporter gene ex-
pression (Soriano, 1999). Our fi  ndings demonstrate that this 
promoter becomes activated at two distinct points during devel-
opment. Expression of the Col3.6-Cre transgene as determined 
by  β-galactosidase activity is fi   rst detected in whole-mount 
stainings of E8–19 embryos and is localized initially to the cau-
dal portion of the embryo. Reporter gene expression is strongest 
in this region at E10 (Fig. 1 B). This region of the developing 
embryo contains both neural and mesenchymal progenitor cells 
that give rise to the caudal axial skeleton and spinal cord. Later 
in development ( E14), the Col3.6-Cre transgene undergoes ro-
bust activation in relation to the formation of connective tissue.
Staining of sagital sections of R26R/Col3.6-Cre embryos
for β-galactosidase activity indicates that Cre-  mediated exci-
sion occurs in both the skin and developing skeletal elements 
(Fig. 1 C). These fi  ndings indicate that Cre transgene expression 
will induce Mdm2 deletion in Col3.6-Cre × Mdm2-  conditional 
mice in the surface ectoderm and developing tail bud of E9 mice 
as well as in developing bone and connective tissue of these 
mice during midgestation.
Table I. Embryonic lethality of Mdm2-conditional Col3.6-Cre mice
Developmental stage Mdm2 mutant/total 
embryos
Percentage of total
E8.5–10.5 9/36 25
E12.5 8/33 25
E13.5 2/18 11
E14.5 4/38 11
E15.5–17.5 6/58 10
E18.5–19.5 11/100 11
Postnatal weaning 0/100  0
Figure 2.  Caudal defects in Mdm2-conditional Col3.6-Cre mice. (A–D) 
Homozygous Mdm2-conditional embryos lacking (left) or containing (right) 
the Col3.6-Cre transgene were harvested from timed matings at E10 (A), 
E15 (B), and E17.5 (C). Embryos mutated for Mdm2 were generally 
smaller and displayed obvious runting of the caudal portion of the embryo, 
absence of a tail, and a severe invagination in the posterior dorsal region 
encompassing the lumbar vertebrae (D, double-headed arrow). (E and F) 
Hematoxylin and eosin staining of sagital sections of wild-type (WT) and 
Mdm2-conditional Col3.6-Cre (MT) embryos (E). Arrows identify somites 
that are surrounded by primitive neural tissue and by developing dorsal 
root ganglia. Mutant embryos lack developing neural tissue and posterior 
dorsal root ganglia (arrowheads), leaving caudal somites externalized (F). 
(G) TUNEL staining performed on serial sections shown in F demonstrates 
increased TUNEL-positive apoptotic cells in the caudal somites and sur-
rounding tissue of mutant embryos in comparison to wild-type littermates.JCB • VOLUME 172 • NUMBER 6 • 2006  912
Caudal defects in Mdm2-conditional 
Col3.6-Cre mice
We crossed Mdm2-conditional mice (Mdm2
sjcnd1/+ or 
Mdm2
sjcnd1/sjcnd1) to Col3.6-Cre–transgenic mice containing 
one conditional Mdm2 allele (Mdm2
sjcnd1/+,Col3.6-Cre). The 
  resulting litters contained Mdm2
sjcnd1/sjcnd1,Col3.6-Cre mice 
(designated as mutant), as well as Mdm2
+/+,Col3.6-Cre mice 
and Mdm2
sjcnd1/+,Col3.6-Cre mice. These last two groups of 
mice were indistinguishable from wild-type mice, which was 
  expected, given that Mdm2 heterozygous mice were previ-
ously found to display no morphologic developmental defects 
(Jones et al., 1995).
To examine the effects of Mdm2 loss during develop-
ment, timed matings of Mdm2
sjcnd1/+,Col3.6-Cre–transgenic 
mice were performed and embryos harvested and genotyped at 
various times after coitum. Expected numbers of mutant Mdm2 
embryos were recovered between E8.5 and -12.5 (Table  I). 
However, reduced numbers of mutant embryos were found at 
E13.5 and throughout later stages of development, and no vi-
able Mdm2
sjcnd1/sjcnd1,Col3.6-Cre mutant mice were recovered 
at weaning or at birth, demonstrating that deletion of Mdm2 
in Col3.6-Cre–transgenic mice induces lethality during later 
stages of embryogenesis.
Defects in the developing tail bud region of mutant mice 
were apparent as early as E10.5, and caudal runting was seen 
in all mutant mice throughout later stages of development 
(Fig. 2, A–C). Col3.6-Cre–induced deletion of Mdm2 expres-
sion in the caudal region of mutant mice resulted in a complete 
absence of tissue surrounding the somites at E10.5, as well as 
exposure of somitic mesenchyme at the surface of the embryo, 
absence of a tail, and a severe invagination in the posterior 
dorsal region encompassing the lumbar vertebrae (Fig. 2 D). 
Histologic analysis of mutant and wild-type embryos har-
vested at E10 was performed. Wild-type embryos had clearly 
segmented somites that will give rise to axial skeletal compo-
nents, including vertebrae and ribs (Fig. 2 E, arrows). These 
somites are surrounded by primitive neural tissue and by 
  developing dorsal root ganglia (Fig. 2 E, arrowheads). In con-
trast, mutant embryos lack developing neural tissue and poste-
rior dorsal root ganglia, leaving caudal somites externalized 
(Fig. 2 F). To understand the mechanism underlying this tissue 
loss, we performed TUNEL staining on serial sections. Our 
results show that there is a dramatic increase in TUNEL-
  positive apoptotic cells in the caudal somites and surrounding 
  tissue of mutant E10 embryos in comparison to wild-type 
  littermates (Fig. 2 G).
Figure 3.  Excision of Mdm2 in skeletal tissues 
results in impaired bone formation.  Alcian 
blue and alizarin red staining of skeletal prep-
arations of wild-type (WT) and Mdm2
sjcnd1/sjcnd1,
Col3.6-Cre (MT) embryos. (A and B) Mutant 
embryos harvested at E17.5 revealed highly 
dysplastic axial skeletal elements with fused 
cartilaginous lumbar vertebrae. (C) The skulls 
of Mdm2
sjcnd1/sjcnd1,Col3.6-Cre E17.5 embryos 
are highly porous, and (D) appendicular bones 
of the forelimb were shorter in length in com-
parison to wild-type littermates. Skeletal pre-
parations of wild-type neonatal mice and 
neonates deleted for both Mdm2 and p53 re-
vealed no vertebral dysplasia (E) or reduction 
in bone length (F), indicating that the deleteri-
ous effects of Mdm2 loss on skeletal formation 
during development are p53 dependent.MDM2–P53 REGULATION OF OSTEOGENESIS • LENGNER ET AL. 913
Excision of Mdm2 in skeletal tissues 
results in impaired bone formation
Skeletal preparations of wild-type and Mdm2
sjcnd1/sjcnd1,Col3.6-
Cre embryos revealed that the apoptosis observed in the E10 
caudal somatic cells resulted in highly dysplastic axial skeletal 
elements in the mutant embryo with fused cartilaginous lumbar 
vertebrae (Fig. 3, A and B). However, the appendicular skeleton 
and bones of the skull were unaffected by the initial Cre 
  activation. Activation of Col3.6-Cre transgene expression in the 
limbs and skull did not occur until the latter half of gestation 
(beginning at E14.5). These skeletal elements were more po-
rous in mutant animals (Fig. 3 C), and measurements of the long 
bones (tibia, radius, ulna, humerus, and femur) revealed that the 
total long bone length was 12.1 ± 3.9% shorter in the mutant 
embryos and the length of mineralized portion of long bones 
was 12.3 ± 4.4% shorter in the mutant embryos than in wild-
type littermate embryos at E17.5 (Fig. 3 D). In contrast, skeletal 
preparations of embryos deleted for both Mdm2 and p53 (Jones 
et al., 1995) revealed no vertebral dysplasia or reduction in bone 
length (Fig. 3, E and F). These results reveal that the deleterious 
Figure 4.  Altered mineralization and mor-
phology observed in Mdm2 mutant mice. 
(A) Micro-CT analysis of skulls of wild-type; 
Mdm2
sjcnd1/sjcnd1,Col3.6-Cre (Mdm2 mutant); 
p53-null; and Mdm2/p53 double-null E18.5 
embryos reveals reduced bone mineralization 
in Mdm2 mutant mice. Histomorphometric 
measurements of bone volume versus total vol-
ume are provided in Table II for each skull, 
with a representative area analyzed for the 
Mdm2/p53-null sample outlined in red. Micro-
CT scan of femur and vertebra (L3–5 region) of 
Mdm2 of wild-type E18.5 embryo (B) and 
Mdm2 mutant embryo (C). Regions of bones 
analyzed in Table II are outlined in red and 
shown in expanded view. Von Kossa (silver ni-
trate) and toluidine blue staining of sagital sec-
tions of femur (D) from Mdm2-conditional 
Col3.6-Cre (MT) mice showed a relatively nor-
mal growth plate region but had signiﬁ  cantly 
less mineral deposition than Mdm2-conditional 
mice lacking the Cre transgene (WT).   Similarly, 
less mineralization was also detected in Von 
Kossa and toluidine blue staining (E) of Mdm2-
conditional Col3.6-Cre vertebra compared 
with wild-type vertebra.JCB • VOLUME 172 • NUMBER 6 • 2006  914
effects of Mdm2 loss on skeletal formation during development 
are p53 dependent.
Appendicular and skull bones from E18.5 Mdm2
sjcnd1/sjcnd1,
Col3.6-Cre mice showed signifi  cantly less mineral deposition 
than wild-type littermates, as assessed by microcomputed to-
mography (micro-CT) scan (Fig. 4, A–C) and by silver nitrate
(Von Kossa) staining (Figs. 4, D and E). Decreased bone mineral-
ization was observed in the skull (Fig. 4 A), femur, and vertebra 
(Fig. 4, B and C) of Mdm2 mutant mice. Histomorphometric 
analysis of micro-CT scans performed on litter-matched, E18.5 
embryos revealed reduced bone density in the calvaria, femur, and 
vertebra of Mdm2 mutant mice (Table II). However, these defects 
were not observed in embryos lacking both Mdm2 and p53. These 
results demonstrate that loss of Mdm2 in developing skeletal tis-
sues negatively affects multiple parameters of bone quality in a 
p53-dependent manner. Furthermore, Von Kossa and toluidine 
blue staining of femur and vertebra sections (Fig. 4, D and E) re-
vealed that the vascularized marrow cavity and other normal com-
partments of bone are present in the mutant mice and that Mdm2 
mutant bone has a morphologically normal growth plate. These 
data suggest that Mdm2 mutant mice do not have a chondrogenic 
defect but rather a defect in ossifi  cation. However, unlike the pro-
apoptotic effects of Mdm2 deletion in undifferentiated progenitor 
cells in E10 mutant mice, TUNEL assays performed on E14.5 
skeletal rib elements from mutant embryos revealed no increase 
in the number of apoptotic cells (unpublished data).
Negative regulation of p53 
by Mdm2 is required for proper 
osteoblast differentiation
To better understand the underlying cause of the decrease in 
bone quality in Mdm2-conditional Col3.6-Cre mice, calvarial 
osteoprogenitor cells were isolated from E19 wild-type and mu-
tant embryos as well as from R26R/Col3.6-Cre embryos to 
  visualize the pattern of Cre-mediated excision in these cultures. 
Calvarial osteoprogenitors were induced to undergo osteogenic 
differentiation ex vivo by allowing cultures to proliferate for 
several days followed by the addition of ascorbic acid and inor-
ganic phosphate to the media postconfl  uence. The addition of 
ascorbic acid to the cultured osteoprogenitors stimulates post-
confl  uent proliferation, resulting in the formation multilayered 
nodules that later become mineralized (Owen et al., 1990). 
  Examination R26R/Col3.6-Cre osteoprogenitor cells reveals 
that few osteoprogenitor cells had activated the transgene before 
isolation from the embryo and that Cre expression is induced in 
the osteoblast cultures during differentiation (Fig. 5 A). Because 
Cre-mediated recombination occurs in these cultures in matur-
ing osteogenic nodules after reaching confl  uence, Mdm2 ex-
pression in Mdm2-conditional Col3.6-Cre cultures should be 
lost in multilayering nodules of maturing osteoblasts.
Toluidine blue staining of calvarial osteoprogenitor cells 
cultured from wild-type and Mdm2-conditional Col3.6-Cre 
mice revealed that both wild-type and Mdm2 mutant–derived 
osteoprogenitor cultures achieved confl  uence  simultaneously 
(Fig. 5, B and C, left), and BrdU incorporation indicated no dif-
ference in the rates of cell proliferation in these cultures before 
confl  uence (not depicted). However, upon reaching confl  uence 
and upon robust induction of Cre expression, wild-type osteo-
progenitor cell cultures underwent robust nodule formation 
(Fig. 5 B), whereas Mdm2
sjcnd1/sjcnd1,Col3.6-Cre cultures were 
unable to form a signifi  cant number of multilayered nodules. 
Subsequently, only a small fraction of the mutant cells were 
able to undergo osteoblast differentiation as refl  ected by alka-
line phosphatase activity (Fig. 5 C). Consistent with our in vivo 
fi  ndings of reduced mineralization in Mdm2 mutant bone, wild-
type osteoblasts ultimately formed heavily mineralized nodules 
in culture, whereas mutant cells failed to deposit signifi  cant 
mineral in the extracellular matrix (Fig. 5, B and C) as deter-
mined by silver nitrate staining (right).
Quantitative analysis by real-time PCR of osteogenic gene 
expression revealed that both wild-type and mutant cultures be-
gan to activate early osteogenic genes type I collagen and alka-
line phosphatase upon reaching confl  uence. However, osteogenic 
gene expression was abrogated in Mdm2 mutant cultures shortly 
after achieving confl  uence (Fig. 5 D, dashed lines). Osteocalcin, 
a marker of late osteoblast differentiation, was not activated in 
mutant cultures at any time during the culture period (Fig. 5 D). 
Because osteoblast differentiation and expression of these 
  osteoblast phenotypic genes is dependent on the activity of the 
Runt-related transcription factor Runx2 (Ducy et al., 1997; 
  Komori et al., 1997; Otto et al., 1997), we next examined the 
impact of Mdm2 loss on the activity of this gene. Real-time 
PCR analysis revealed that Mdm2 and Runx2 are expressed at 
low levels in wild-type cultures during the period of prolifera-
tion but are strongly activated in postconfl  uent cultures during 
multilayering and differentiation. However, as expected, Mdm2 
up-regulation is abrogated in osteoprogenitor cultures derived 
from Mdm2-conditional Col3.6-Cre mice during the course of 
differentiation (Fig. 5 E). Interestingly, both Runx2 protein and 
message levels were lost in mutant cultures concomitantly with 
the loss of Mdm2 expression (Fig. 5, E and F). Furthermore, 
  although the G1/S ratio of preconfl  uent osteoprogenitor cells 
Table II. Morphometric analysis and quantitative analysis of bones
Genotype Skull width Skull length L3-5 spine Calvaria Femur Vertebra
mm mm mm % % %
Wild type 8.1 10.1 2.2 93.0 28.4 51.7
Mutant 5.2 7.7 1.3 31.5 12.7 BT
p53 null 7.8 10.3 2.2 88.0 16.4 40.8
Mdm2/p53 null 8.0 9.9 2.4 90.3 18.1 48.4
Data obtained from representative (E18.5) littermate embryos. Measurements are given in millimeters. Quantitative analysis is expressed as percentage of bone density 
as determined by the amount of bone per tissue volume (bone volume over total volume). Below threshold (BT) means bone volume was below detectable levels.MDM2–P53 REGULATION OF OSTEOGENESIS • LENGNER ET AL. 915
was unchanged in Mdm2-conditional Col3.6-Cre cells (before 
induction of Cre expression), postconfl  uent cycling of mutant 
cells deleted for Mdm2 was strongly inhibited as determined by 
BrdU uptake assays, with a G1/S ratio of 7.5:4.2 for nonmutant 
cells. In addition, no differences in apoptotic cell numbers were 
detected by TUNEL assays during differentiation of cultured 
osteoblast progenitor cells after Cre-mediated deletion of Mdm2 
(unpublished data). Collectively, our results indicate that Mdm2 
activity is required for postconfl  uent cell proliferation and nod-
ule formation in osteoblast cultures and the subsequent activa-
tion of the master osteoblast transcriptional regulator Runx2. 
Failure of cultures lacking Mdm2 to activate the Runx2 gene 
ultimately results in inhibition of osteoblast differentiation and 
inactivity of osteoblast phenotypic genes. To confi  rm that re-
duced Runx2 expression in the Mdm2 mutant cells is the under-
lying cause of the maturation defect, recombinant adenovirus 
vectors were generated to transduce either lacZ (control) or 
Runx2 cDNA into the osteoblast progenitor cultures. Addition 
of exogenous Runx2 into Mdm2 mutant cells induced matura-
tion of these progenitor cells and partially or fully restored the 
expression of mature osteogenic genes such as collagen type 1, 
alkaline phosphatase, and osteocalcin (Fig. 5 G).
Examination of p53 levels in ex vivo osteoblast cultures 
revealed no change in total p53 protein levels in cultures under-
going deletion of Mdm2 (Fig. 6 A). However, a difference in the 
amount of activated p53 transcription factor present in the cul-
tures was detected using a phospho-Ser15 specifi  c antibody, 
with a marked induction in P-Ser15 p53 levels observed in mu-
tant cultures relative to levels in wild-type cells (Fig. 6 B), sug-
gesting that Mdm2 negatively regulates p53 activity but not 
overall p53 protein levels in differentiating osteoblasts. Further-
more, real-time PCR analysis revealed up-regulation of Ptprv 
and p21 gene expression (Fig. 6, C and D) in postconfl  uent os-
teoblast cultures derived from Mdm2-conditional Col3.6-Cre 
Figure 5.  Mdm2 is required for proper 
  osteoblast differentiation. Calvarial osteopro-
genitor cells were isolated and cultured ex 
vivo from E19 Col3.6-Cre–transgenic em-
bryos bearing the R26R reporter gene, from 
E19 wild-type and Mdm2-conditional Col3.6-
Cre–transgenic embryos. Calvarial osteopro-
genitors were induced to undergo osteogenic 
differentiation ex vivo, resulting in proliferation 
(toluidine blue staining for total cell number), 
the formation of multilayered nodules and 
  activation of alkaline phosphatase, and min-
eralization as detected by silver nitrate 
  staining. (A) Examination R26R/Col3.6-Cre 
osteoprogenitor cells stained for β-galactosi-
dase activity reveals that Mdm2 expression 
in Mdm2-conditional Col3.6-Cre cultures will 
be lost in multilayering nodules of maturing 
osteoblasts. (B) Upon reaching conﬂ  uence, wild-
type osteoprogenitor cell cultures underwent 
robust nodule formation and mineralization. 
(C) Mdm2-conditional Col3.6-Cre–transgenic 
cultures were unable to form a signiﬁ  cant num-
ber of multilayered nodules, and subsequently 
only a small fraction of these cells were able 
to undergo differentiation, activate alkaline 
phosphatase activity, or induce mineraliza-
tion. (D) Quantitative analysis by real-time 
PCR of the expression of early osteogenic 
genes type I collagen (Coll) and alkaline phos-
phatase (AP) and of osteocalcin (OC) at vari-
ous stages of osteoblast maturation. Solid 
lines depict the relative transcript levels of 
genes in wild-type cell cultures, and dashed 
lines represent the levels of expression of the 
various genes in Mdm2-conditional Col3.6-
Cre cell cultures. Expression levels of early 
and late osteogenic genes are reduced in 
Mdm2-conditional Col3.6-Cre–transgenic cells. 
(E) Real-time PCR analysis of Mdm2 and 
Runx2 expression in wild-type (WT) and 
Mdm2-conditional Col3.6-Cre–transgenic (MT) 
culture osteoblast progenitor cells during 
maturation. Solid and dashed lines depict the 
relative transcript levels of Mdm2 and Runx2 in wild-type or Mdm2-conditional Col3.6-Cre–transgenic cultures, respectively. As expected, Mdm2 levels do 
not increase in Mdm2-conditional Col3.6-Cre–transgenic cells during maturation. Similar induction of Runx2 and Mdm2 expression is observed in wild-type 
cells during maturation. (F) Western blot analysis of Runx2 protein levels in wild-type or Mdm2-conditional Col3.6-Cre–transgenic culture osteoblast pro-
genitor cells during maturation and mineralization. Lamin-b is shown as a loading control. Decreased amounts of Runx2 protein are observed in Mdm2-
conditional Col3.6-Cre–transgenic cells. (G) Quantitative PCR was performed on reverse-transcribed RNA isolated from osteoblast progenitor cells 
transduced with Runx2 or lacZ (negative control). Exogenous Runx2 up-regulated the expression of osteogenic maturation genes in Mdm2 mutant cells, 
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mice (dashed lines) relative to expression levels observed in 
Col3.6-Cre cells containing wild-type Mdm2 alleles (solid 
lines). These genes are targets of p53 transactivation known to 
be involved in regulating the progression of primary cells from 
G1 into S phase of the cell cycle (Deng et al., 1995; Doumont 
et al., 2005). This increase in Ptprv and p21 expression is con-
sistent with the inhibition of postconfl  uent osteoprogenitor cell 
growth observed in the Mdm2-conditional Col3.6-Cre cultures. 
Interestingly, the expression levels of Bax and Puma, two pro-
apoptotic p53 response genes, were not signifi  cantly altered in 
osteoblast progenitor cells after deletion of Mdm2 (unpublished 
data), consistent with the unaltered level of apoptosis in Mdm2 
mutant and wild-type cells.
Regulation of osteoprogenitor 
differentiation and osteosarcoma 
formation by p53
Our fi  ndings indicate that loss of Mdm2 results in a block in 
osteoblast differentiation that is due to excess p53 activity. 
To confi  rm that p53 negatively regulates bone maturation and 
mineralization, we examined the differentiation of osteoprogen-
itor cells harvested from the calvaria of p53-null mice.   Calvarial 
osteoprogenitor cells were isolated from E19 wild-type or p53-
null mice and induced to undergo osteogenic differentiation. 
The addition of ascorbic acid to the cultured osteoprogenitors 
greatly increased postconfl   uent proliferation in the p53-null 
cultures relative to wild-type cultures, resulting in increased 
formation of multilayered nodules and excess mineralized bone 
formation (Fig. 7 A). BrdU staining and FACS analysis of post-
confl  uent osteoprogenitor cells revealed fewer p53-null cells in 
G1 and more in S phase (Fig. 7 B). Furthermore, real-time PCR 
analysis of Runx2 transcripts in the ex vivo cultures revealed a 
dramatic increase in the Runx2 expression levels during matura-
tion and mineralization when p53 was absent (Fig. 7 C). These 
data confi  rm that p53 negatively regulates osteoblast prolifera-
tion and differentiation. Notably, there was a difference in the 
ex vivo maturation of p53-null and Mdm2/p53 double-null os-
teoblast progenitor cells (Fig. 7 D), underscoring our previous 
in vivo fi  ndings (Fig. 3 E and Fig. 4 A) of a p53-dependent role 
for Mdm2 in regulating skeletal development.
Increased proliferation of osteoprogenitor cells in the cal-
varial cultures suggests that negative regulation of osteoblast 
progenitor cell proliferation and differentiation by p53 may be 
an important component of p53-mediated suppression of bone 
tumorigenesis. To explore a link between negative regulation of 
osteoblast growth and neoplasia, we bred the Col3.6-Cre mice 
with p53-conditional mice (Marino et al., 2000). Cohorts of 
transgenic Col3.6-Cre mice that were either homozygous or 
heterozygous for the p53-conditional allele were used to per-
form a tumor assay. Col3.6-Cre mice heterozygous for the p53-
conditional allele developed mostly bone masses starting at 
20 wk of age, and all mice in the colony presented with cancer 
by 82 wk, whereas Col3.6-Cre mice homozygous for the p53-
conditional allele all presented with tumors by 42 wk (Fig. 7 E). 
Histopathologic analysis of p53-conditional Col3.6-Cre mouse 
tumors identifi  ed 60% of these cancers as osteosarcomas, with 
a 20% incidence of lymphoma or fi  brosarcoma. Most of the os-
teosarcomas were classifi  ed as high grade and were of interme-
diate differentiation, producing osteoid but not mature lamellar 
bone (Fig. 7 F, samples PT2, -50, and -38). However, a few of 
the osteosarcoma tumors were especially aggressive and very 
poorly differentiated (Fig. 7 F, sample PT58). Western blot 
analysis of representative primary tumor samples harvested 
from these mice indicated that Runx2 expression was greatly 
elevated specifi  cally in osteosarcomas, regardless of their dif-
ferentiation (Fig. 7 G, lanes 1–3). These results confi  rm that p53 
not only down-regulates osteoblast cell growth and differentia-
tion during development but also plays a critical role in sup-
pressing osteosarcoma formation in adult bone tissue.
Discussion
The rescue of Mdm2-null mice from peri-implantation lethal-
ity by deletion of p53 demonstrates that Mdm2 plays an im-
portant role in early development by negatively regulating p53 
activity (Jones et al., 1995; Montes de Oca Luna et al., 1995), 
Figure 6.  Deletion of Mdm2 alters p53 activity in osteoblast cultures. 
(A) Western analysis of p53 levels in wild-type (WT) and Mdm2-  conditional 
Col3.6-Cre–transgenic (MT) osteoprogenitor cells during differentiation re-
veals no change in total p53 protein levels in cultures undergoing deletion 
of Mdm2. (B) Western analysis of phosphorylated p53 in wild-type and 
Mdm2-conditional Col3.6-Cre–transgenic cells during maturation and min-
eralization reveals increased amounts of activated p53 in MT cells. Lamin-b 
is shown as a loading control. (C and D) Real-time PCR analysis of RNA 
isolated from wild-type or Mdm2-conditional Col3.6-Cre–transgenic cells 
during differentiation reveals up-regulation of Pptrv or p21 gene expres-
sion in postconﬂ   uent osteoblast cultures derived from Mdm2-conditional 
Col3.6-Cre mice (dashed line) relative to expression levels in cells contain-
ing wild-type Mdm2 alleles (solid line). Error bars indicate SD.MDM2–P53 REGULATION OF OSTEOGENESIS • LENGNER ET AL. 917
but little is known about the requirement for Mdm2 throughout 
embryogenesis and in postembryonic tissues. We previously 
documented that the growth characteristics of p53-null primary 
fi  broblasts and the tumorigenic potential of p53-null mice are 
indistinguishable in the presence or absence of Mdm2 (Jones 
et al., 1996). Thus, if Mdm2 was important in the latter stages 
of development, in organogenesis, or in postnatal cell growth 
control, it is likely due to the ability of Mdm2 to down-  regulate 
p53 activity and not to p53-independent effects of Mdm2. 
In support of a role for Mdm2 in regulating p53 during the lat-
ter stages of development, recent studies of mice that contain 
reduced amounts of Mdm2 relative to wild-type levels indicate 
that Mdm2 regulates p53 activity in hematopoietic development 
and in B cell tumorigenesis (Alt et al., 2003; Mendrysa et al., 
2003). However, the effect of complete ablation of Mdm2 activ-
ity on cellular differentiation and in organogenesis is unknown.
Coordinated proliferation and differentiation of bone-
forming osteoblast progenitor cells and the deposition of ex-
tracellular matrix proteins by osteoblasts and subsequent 
deposition of crystalline salts for mineralization of the skeleton 
are two critical steps in bone modeling both during development 
and in the adult skeleton (Harada and Rodan, 2003). Although 
Figure 7.  Regulation of osteoblast progenitor 
differentiation and osteosarcoma formation 
by p53. Calvarial osteoprogenitor cells were 
cultured ex vivo from E19 wild-type (WT) and 
p53-null embryos. (A) Calvarial osteoprogeni-
tors were induced to undergo osteogenic dif-
ferentiation, resulting in proliferation (toluidine 
blue), maturation and the formation multilay-
ered nodules and activation of alkaline phos-
phatase, and mineralization as detected by 
silver nitrate staining. Osteoprogenitor cells de-
leted for p53 displayed far more proliferation 
than wild-type cells cultured at the same initial 
density, increased alkaline phosphatase, and 
increased mineralization. (B) Proliferation was 
documented by BrdU uptake in postconﬂ  uent 
cultures of wild-type and p53-null progenitor 
cells just before cell maturation. The percent-
age of cells in each phase of the cell cycle 
was determined by FACS analysis after prop-
idium iodide staining of the harvested cells. 
Postconﬂ  uent p53-null cells had more cells in 
S phase than wild-type cells. (C) Real-time PCR 
analysis of Runx2 expression in wild-type and 
p53-null cultures of osteoblast progenitor cells 
during maturation. Runx2 transcript levels are 
strongly up-regulated in p53-null cells during 
maturation. (D) No difference was observed 
in the robust osteoprogenitor cell differen-
tiation in p53-null cells that contained (top) or 
lacked (bottom) Mdm2. (E)   Tumorigenesis in 
mice deleted for p53 in osteoblasts. Col3.6-
Cre–transgenic mice heterozygous for a con-
ditional p53 allele (p53-cond/wild type) or 
homozygous for the p53-conditional allele 
(p53-cond/cond) were assayed for sponta-
neous tumor development. A majority of the 
mice presented with osteosarcomas, with 
a mean time to tumorigenesis of 40 wk for 
Col3.6-Cre, p53-cond/cond mice and 57 wk 
for Col3.6-Cre, p53-cond/wild-type mice. (F) 
  Hematoxylin and eosin stains of osteosarco-
mas harvested from Col3.6-Cre, p53-cond/
cond mice. Samples PT2, -50 (showing inva-
sion into the liver), and -38 are all more dif-
ferentiated than sample PT58, which displays 
a spindle-like morphology in addition to some 
osteoid cells. (G) Analysis of Runx2 protein 
levels in representative primary tumor samples 
from p53-conditional Col3.6-Cre mice. Runx2 
levels were readily detected in representative 
osteosarcomas (lanes 1–3: samples PT2, -38, 
and -58, respectively) but reduced in ﬁ  bro-
sarcoma (lane 4), lymphoma (lane 5), or 
hemangiosarcoma (lane 6) samples.JCB • VOLUME 172 • NUMBER 6 • 2006  918
little is known regarding the role of p53 in this process, previous 
studies of mice bearing a hypermorphic p53 mutation revealed 
that mice with increased amounts of p53 activity exhibit symp-
toms of rapid aging, including osteoporosis (Tyner et al., 2002). 
Furthermore, a subset of mice haploinsuffi  cient for functional 
p53 in all tissues develop osteosarcomas (Harvey et al., 1993b). 
These data suggest that p53 may regulate normal bone growth 
and that alterations in the levels of p53 activity can contribute to 
abnormal bone phenotypes.
To further explore a role for p53 in osteogenesis and to 
determine whether Mdm2–p53 signaling is important in bone 
growth and development, we bred Mdm2-conditional mice with 
Col3.6-Cre–transgenic mice. Deletion of Mdm2 upon expres-
sion of the Col3.6-Cre transgene resulted in midgestational cau-
dal defects, including loss of tissue surrounding the somites, 
exposure of somitic mesenchyme at the surface of the embryo, 
absence of a tail, and a severe caudal invagination. Furthermore, 
TUNEL staining of serial sections of mutant embryos revealed 
increased apoptosis in the caudal somites and surrounding tissue 
of mutant embryos, suggesting that these defects arose through 
unregulated p53 apoptosis. Harvests of embryos from timed mat-
ings of Mdm2-conditional Col3.6-Cre–transgenic mice revealed 
a marked decrease in the recovery of Mdm2
sjcnd1/sjcnd1,Col3.6-Cre 
embryos at E13.5, coincident with the robust activation of the 
Cre transgene in developing skeletal elements. Skeletal prepara-
tions of wild-type and of Mdm2
sjcnd1/sjcnd1,Col3.6-Cre embryos 
documented numerous skeletal defects during the latter stages 
of development, including a reduction in mineralized bone and 
in length of appendicular bone, abnormal bone architecture, and 
an increase in bone porosity. However, analysis of skeletal prep-
arations of embryos deleted for both Mdm2 and p53 revealed no 
skeletal defects, and no difference was observed in the growth 
and maturation of cultured calvarial cells defi  cient for p53 or for 
both Mdm2 and p53, indicating that the effects of Mdm2 loss on 
skeletal formation and osteoblast maturation are p53 dependent. 
In contrast to what was observed in the caudal mesoderm of 
E10 mutant embryos, TUNEL assays performed on E14.5 bone 
isolated from Mdm2-conditional Col3.6-Cre embryos and on 
osteoprogenitor cells cultured from E19 Mdm2-conditional 
Col3.6-Cre embryos revealed no increase in the number of 
apoptotic cells. This fi  nding indicates that deletion of Mdm2 
does not induce p53-mediated apoptosis in these cells but rather 
induces p53-mediated effects that block osteoblast proliferation 
or differentiation. To confi  rm that p53 plays a role in regulating 
osteoblast differentiation, we harvested osteoblast progenitor 
cells from the calvarial of p53-null mice just before birth (E19). 
Analysis of the growth and development of these cultured cells 
revealed that p53-null osteoprogenitor cells proliferated far 
faster than wild-type progenitor cells and underwent more ro-
bust differentiation, confi  rming that p53 functions to negatively 
regulate osteoblast maturation and mineralization.
Surprisingly, the overall level of p53 protein did not 
change in osteoblast cells during differentiation in the presence 
or absence of Mdm2; however, deletion of Mdm2 did result in 
an increase in the level of activated p53 as judged by the in-
creased levels of phosphorylated p53. Furthermore, the message 
levels of Pptrv and the cyclin-dependent kinase inhibitor p21, 
two p53 target genes involved in regulating cell cycle progres-
sion from G1 to S phase, were increased in osteoblast cells after 
Mdm2 deletion. These results indicate that Mdm2 regulates p53 
activity during osteoblast differentiation not by altering p53 sta-
bility but by inhibiting p53-mediated transactivation of genes 
involved in regulating osteoblast growth and differentiation.
Runx2 is a critical inducer of osteoblast differentiation 
in vitro and in vivo (Stein et al., 2004). Interestingly, levels 
of Runx2 message and protein were reduced in cells deleted 
for Mdm2, as were the message levels of Runx2 target genes 
type I collagen and alkaline phosphatase. In addition, expres-
sion of osteocalcin, a marker of late osteoblast differentiation, 
was not activated in cultures deleted for Mdm2 during differ-
entiation, providing further molecular evidence for a block in 
osteoblast development upon deletion of Mdm2. In contrast to 
the reduction in Runx2 levels observed in osteoblasts deleted 
for Mdm2, Runx2 message levels were found to be greatly el-
evated in maturing osteoblasts deleted for p53. As Runx2 is a 
well-established master regulator of osteoblast differentiation, 
it is possible that p53 directly controls osteoblast maturation 
by negatively regulating Runx2 expression. However, analysis 
of the Runx2 promoter sequences failed to identify any p53 ca-
nonical binding sites, and there is no evidence present in the 
literature to suggest that Runx2 expression is directly regulated 
by p53. Therefore, we hypothesize that proper osteoblast dif-
ferentiation and bone development require Mdm2 to inhibit a 
p53-mediated block on osteoprogenitor cell division. By per-
mitting the postconfl  uent proliferation of osteoblasts through 
the down-regulation of p53 activity, Mdm2 indirectly facilitates 
Runx2 induction and osteoblast maturation. In support of this 
hypothesis, expression levels of mature osteogenic genes were 
found to be elevated in Mdm2 mutant osteoblasts after restora-
tion of Runx2 expression.
Our results indicate that up-regulation of p53 activity due 
to Mdm2 deletion induces a block in bone differentiation and 
mineralization and causes profound skeletal defects in the de-
veloping embryo. Furthermore, deletion of p53 in osteoblasts 
induces hyperproliferation, greatly elevated levels of Runx2 
expression, and increased bone maturation in vitro. These fi  nd-
ings indicate that p53 is an important negative regulator of bone 
growth and development. Interestingly, loss of cell differentia-
tion and reduced expression of mature osteogenic genes such as 
Osteocalcin are prognostic indicators in human osteosarcomas, 
with poorly differentiated or dedifferentiated tumors usually 
associated with the high-grade category (Hopyan et al., 1999). 
In addition, Runx2 is down-regulated in various human osteo-
sarcoma cell lines, suggesting a link between loss of Runx2 
expression, dedifferentiation, and cancer (Thomas et al., 2004). 
However, we observed increased osteoblast differentiation and 
elevated Runx2 expression in osteoblast progenitor cells de-
rived from p53-null mice. Therefore, we examined the ability of 
p53 to suppress tumorigenesis in osteoprogenitor-derived cells 
by crossing Col3.6-Cre–transgenic mice with p53-  conditional 
mice (Marino et al., 2000). Our results indicate that loss of 
p53 in osteoblasts induces a fairly rapid tumorigenesis in mice. 
  Interestingly, Col3.6-Cre–transgenic mice heterozygous or 
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tumor onset similar to those that have been previously docu-
mented for p53 knockout heterozygous or homozygous mice, 
though the tissue specifi   city of tumorigenesis was greatly 
altered. Mice deleted for p53 in all tissues die predominantly 
from lymphomas, chiefl  y of the thymus, and only occasionally 
will present with bone tumors (Harvey et al., 1993b). Depend-
ing on the genetic background of the mice, between 3 and 8% 
of p53-null mice develop osteosarcomas (Harvey et al., 1993a; 
Jones et al., 1996). However, this tumor spectrum may refl  ect 
the critical importance of p53 in suppressing thymic lymphomas 
in relatively young mice and not a reduced role for p53 in sup-
pressing bone cancer, as osteosarcomas do constitute approxi-
mately one third of all tumor types observed in the longer lived 
p53 heterozygous mice (Harvey et al., 1993b). A majority of 
the Col3.6-Cre–transgenic, p53-conditional heterozygous mice 
or p53-conditional homozygous mice in our study developed 
osteosarcomas. Furthermore, Runx2 expression was elevated 
in primary osteosarcoma samples harvested from these mice, 
in agreement with our fi  nding of increased Runx2 expression in 
the p53-null calvarial cell cultures.
The results of our p53-conditional Col3.6-Cre–transgenic 
mouse cross confi  rm that p53 is a critical tumor suppressor in 
bone tissue and indicate that osteosarcoma formation does not 
require loss of Runx2 expression. Instead, we propose that p53 
inhibition of osteoblast cell proliferation is the mechanistic 
  basis for suppression of bone osteosarcomas in this model. As 
we have demonstrated that Mdm2 is a key regulator of p53 ac-
tivity in osteoblasts, disrupting the ability of Mdm2 to down-
regulate p53 activity in these cells may prove to be a useful 
therapeutic strategy in treating osteosarcomas.
Materials and methods
Mouse lines
Mdm2-conditional mice were developed in our laboratory using standard 
gene targeting techniques in embryonic stem cells. The resulting allele con-
tains two loxP sites ﬂ  anking exons 11 and 12. Upon Cre-mediated recom-
bination, exons 11 and 12 are excised, rendering the allele inactive 
(described in Steinman and Jones [2002]). Mdm2 excision was mediated 
by crossing Mdm2-conditional (Mdm2
sjcnd1) mice to transgenic mice in 
which the 3.6-kb type I collagen promoter governs the expression of the 
Cre-recombinase enzyme (Col3.6-Cre). Visualization of tissues in which 
the Cre-recombinase activity has recombined target alleles was facilitated 
by mating Col3.6-Cre–transgenic mice to R26R reporter mice (The Jackson 
Laboratory) in which Cre expression results in the removal of a loxP-ﬂ  anked 
DNA segment that prevents expression of a lacZ gene. The p53-  conditional 
mouse model (Marino et al., 2000) was obtained from A. Berns 
(Netherlands Cancer Institute, Amsterdam, Netherlands). All animals were 
maintained and used in accordance with the University of Massachusetts 
Animal Care and Use Committee.
Whole-mount and histological analysis
Embryos were harvested from timed pregnant mothers at various time 
points during gestation followed by ﬁ   xation in 4% paraformaldehyde. 
  Tissues destined for histological sectioning were dehydrated in a graded 
series of ethanol and xylene, followed by inﬁ  ltration with parafﬁ  n wax. 
  Tissues from R26R/Col3.6-Cre crosses were ﬁ   xed in 4% paraformalde-
hyde, equilibrated overnight in 30% sucrose, and embedded in optimal 
cutting temperature for cryosectioning. Some embryos were ﬁ  xed in 4% 
paraformaldehyde followed by whole-mount staining for β-galactosidase 
activity. Parraﬁ  n sections were cut at 7 μm and counterstained with eosin. 
Frozen sections were cut at 10–12 μm, stained for β-galactosidase activ-
ity, and counterstained with eosin. β-Galactosidase activity was visualized 
by staining whole embryos, cryosections, or calvarial cultures in a solution 
containing 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 
2 mM MgCl2, 0.2% NP-40, 0.01% sodium deoxycholate, and 1 mg/ml 
X-Gal in PBS, pH 7.4, at 37°C for 1–6 h. Calvarial cultures were stained 
for mineral content using the method of Von Kossa. In brief, sections were 
exposed to a solution of 3% silver nitrite under direct sunlight for 15 min, 
after which mineral deposits were visualized as black precipitate under 
brightﬁ  eld microscopy. Alkaline phosphatase activity in calvarial cultures 
was visualized by colorimetric enzymatic reaction to a solution contain-
ing 0.5 mg/ml napthol as MX phosphate disodium salt (Sigma-Aldrich), 
2.8% N,N dimethylformamide (Sigma-Aldrich), 0.1 M Tris-maleate buf-
fer, pH 8.4, and 1 mg/ml fast red salt (Sigma-Aldrich). The reaction was 
performed at 37°C for 10 min. Decalciﬁ  ed femora and vertebrae were 
embedded in a mixture of methyl methacrylate: glycol methacrylate, sec-
tioned at 2 μm, stained with Von Kossa, and counterstained with toluidine 
blue. TUNEL staining was performed on dewaxed parafﬁ  n sections using 
a ﬂ  uorescein-conjugated in situ cell death detection kit (Roche) according 
to the manufacturer’s protocol.
Skeletal preparations
Skeletons were prepared for visualization of cartilage and bone using al-
cian blue and alizarin red stains, respectively. Embryos were eviscerated 
followed by overnight ﬁ  xation in 100% ethanol. The next day, cartilagi-
nous elements were stained overnight in a solution containing 4 parts 
  ethanol, 1 part glacial acetic acid, and 0.3 mg/ml alcian blue 8GX 
(Sigma-Aldrich). The next day, soft tissues were dissolved for 6 h in a 2% 
KOH solution followed by an overnight staining in a 1% KOH solution con-
taining 75 μg/ml alizarin red S (Sigma-Aldrich). Skeletons were then de-
stained in 20% glycerol and 1% KOH for several days and stored in 50% 
glycerol and 50% ethanol.
Bone micro-CT
Embryos were ﬁ  xed overnight in 4% paraformaldehyde, rinsed three times 
with PBS, and scanned on a Skyscan 1072 instrument (Skyscan). Image 
acquisition of the head was performed using 25× magniﬁ  cation (50× for 
the limb) at 45 kV and 222 μA, with a 0.45° rotation between frames to 
obtain two-dimensional images. Three-dimensional reconstruction and 
quantitative analyses were performed on a computer (Dell) using the NRecon, 
ANT, and CTAn software supplied with the Skyscan instrument.
Calvarial osteoblast preparations
Calvarial osteoblasts were isolated from E19 embryos by enzymatic diges-
tion of calvarial bones. In brief, calvaria were minced and subjected to 
three sequential digestions (8, 10, and 26 min) with collagenase P (Roche) 
at 37°C. Osteoblasts in the second and third digest were collected and re-
suspended in α-MEM supplemented with 10% FBS (HyClone). Cells were 
plated at a density of 10
6 cells/6-well plate (Owen et al., 1990). Differen-
tiation was initiated after conﬂ  uence by the addition of ascorbic acid and 
β-glycerol phosphate. Cultures were harvested at various time points and 
stained for β-galactosidase activity, mineral content, alkaline phosphatase 
activity, or total cellularity using toluidine blue. All osteoblast differentiation 
experiments were performed a total of three times, and each experiment 
used embryos of different genotypes harvested on the same day (E19) from 
the same litter. The proliferation, conﬂ  uence, maturation, and mineraliza-
tion stages of differentiation are deﬁ  ned as days 5, 10, 14, and 20 in cul-
ture, respectively, except for Fig. 6 C, where conﬂ  uence, maturation, and 
mineralization stages of differentiation were reached on days 8, 12, and 
17 of culture, respectively.
Image acquisition
Whole-mount photographic images of embryos (Fig. 1 B and Fig. 2, A–D), 
histologic sections of embryos (Fig. 1 C and Fig. 2, E and F), skeletal preps 
(Fig. 3), and stained osteoblast cultures (Fig. 5, A–C; and Fig. 7, A and D) 
were obtained using a stereoscope (MZ8; Leica) with either a 1× or 
0.63× reduction lens and a digital camera (3008 Prog/Res; JenOptik) 
coupled to a computer (G4; Macintosh), using Photoshop 4 software 
(Adobe). Bone histology images (Fig. 4, D and E) were captured using an 
Axioskop 40 (Carl Zeiss MicroImaging, Inc.) equipped with a camera 
  (AxioCamMRc; Carl Zeiss MicroImaging, Inc.), a Dell computer, and 
MRGrab software. Magniﬁ  cations at source are 2.5× (low power) and 
20× (high power). TUNEL photographic images (Fig. 2 G) were obtained 
using an inverted microscope (model 405; Carl Zeiss MicroImaging, Inc.) 
with a Fluor 10 (10×) plan (Nikon) and a digital camera (SPOT; Diagnos-
tic Instruments) connected to a Dell computer using Photoshop 4 Imaging. 
Tumor hematoxylin and eosin–stained sections (Fig. 7 F) were imaged us-
ing a   microscope (Eclipse E400; Nikon) with a 20× plan (Nikon) coupled 
to a SPOT digital camera and a computer (IBM) with Spot acquisition soft-
ware (4.0.1) and Photoshop 7 software.JCB • VOLUME 172 • NUMBER 6 • 2006  920
Transduction of Runx2 into calvarial cultures
Adenoviral infection of primary mouse osteoblasts was performed at day 
10 of culture (conﬂ  uence) with either a vector expressing Xpress-tagged 
mouse Runx2 under transcriptional control of the cytomegalovirus CMV5 
promoter (pAd/CMV5/Xpress-Runx2/IRES/GFP) or a control vector ex-
pressing LacZ (pAd/CMV5/LacZ/IRES/GFP). Infections were performed 
at a multiplicity of infection of  100 in α-MEM containing 5% FBS 
  (HyClone). 12 h after infection, the media was replaced with α-MEM con-
taining 10% FBS and ascorbic acid to initiate osteogenic differentiation. 
Cultures were harvested 7 d after infection, and quantitative RT-PCR was 
performed on total RNA isolated from each sample.
RNA isolation and analysis
RNA was isolated from tissue or cell cultures using Trizol reagent   (Invitrogen) 
according to the manufacturer’s protocol. After puriﬁ  cation, 5 μg of total 
RNA was DNase treated using a DNA-free RNA column puriﬁ  cation kit 
(Zymo Research). 1 μg RNA was then reverse transcribed using Oligo-dT 
primers and a ﬁ  rst-strand synthesis kit (SuperScript; Invitrogen) according 
the manufacturer’s protocol. Gene expression was assessed by semiquan-
titative (Cre, Mdm2, and glyseraldehyde-3-phosphate dehydrogenase 
[GAPDH]; 25 cycles) and quantitative real-time PCR (Runx2, alkaline phos-
phatase, osteocalcin, collagen type I, and GAPDH). Quantitative PCR was 
performed using SYBR green 2× master mix (Eurogentec) and a two-step 
cycling protocol (anneal and elongate at 60°C and denature at 94°C). 
Speciﬁ  city of primers was veriﬁ  ed by dissociation temperature of amplicons. 
Results are representative of two or more   independent experiments.
Protein analysis
Total protein was isolated from calvarial cultures or from primary tumor sam-
ples in the presence of direct lysis buffer (0.1 M Tris-HCl, pH 7.5, 10% glyc-
erol, 0.01 M DTT, 12% urea, and 2% SDS) followed by heating for 5 min 
at 100°C. 40 μg of total protein was then electrophoresed through a 10% 
acrylamide gel followed by transfer onto a polyvinylidene ﬂ  uoride (Immobi-
lon) membrane. Membranes were blocked in PBS Tween 20 (PBST) contain-
ing 2% nonfat dry milk (Bio-Rad Laboratories) before incubation with 
antibodies. Antibodies were incubated with membranes in the presence of 
PBST containing 2% nonfat dry milk for 1 h at room temperature. Excess pri-
mary antibody was removed with three 10-min washes of PBST. Secondary 
antibodies were incubated with membranes for 1 h at room temperature fol-
lowed by three 10-min washes with PBST to remove excess antibody. 
  Proteins were visualized on the membrane by exposure to Western light-
ning chemiluminescent reagent. The Runx2 antibody was a gift from Y. Ito 
(National University of Singapore, Singapore). Total p53 was detected us-
ing a 50:50 mix of ab-1 and -3 (Oncogene Research Products). Activated 
p53 was detected using an anti-pSer15 p53 antibody (Cell Signaling 
  Technology). All antibodies were used at a concentration of 50 ng/ml.
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